Effects of verapamil on coronary hemodynamic function and vasomobility relative to its mechanism of antianginal action*
References (33)
- et al.
Report on therapy: effect of nitroglycerin, intensain, isoptin and papaverine on coronary bood flow in man
Am J Cardiol
(1966) - et al.
Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease
Am J Cardiol
(1981) - et al.
Antianginal and myocardial metabolic properties of verapamil in coronary artery disease
Am J Cardiol
(1980) - et al.
Effects of intravenous verapamil on hemodynamics in patients with heart disease
Am Heart J
(1977) - et al.
Intravenous dipyridamole combined with isometric handgrip for near maximal acute increase in coronary flow in patients with coronary artery disease
Am J Cardiol
(1981) - et al.
Nifepidine in the treatment of Prinzmetal's angina
Am J Cardiol
(1979) - et al.
Nifedipine in the treatment of unstable angina, coronary spasm and myocardial ischemia
Am J Cardiol
(1981) - et al.
Oral verapamil versus propranolol in coronary artery disease: evaluation of left ventricular function by exercise radionuclide ventriculography (abstr)
Am J Cardiol
(1981) - et al.
Therapeutic implications of slow-channel blockade in cardiocirculatory disorders
Circulation
(1980) - et al.
Calcium channel blocking agents in the treatment of cardiovascular disorders
Ann Intern Med
(1980)
Verapamil: a review of its pharmacological properties and therapeutic use
Drugs
(1978)
Coronary vasodilatory and cardiac adrenergic blocking effects of iproveratnil
Can J Physiol Pharmacol
(1965)
Iproveratnil: experimental data on coronary dilatation and antiarrhythmic action
Can Med Assoc J
(1964)
Coronary cineangiographic study of intravenously administered isoptin
Can Med Assoc J
(1966)
Effect of verapamil on coronary hemodynamics in patients with coronary artery disease
Eur J Cardiol
(1978)
Measurement of coronary sinus blood flow by continuous thermodilution
Circulation
(1971)
Cited by (0)
- *
This study was supported in part by the Medical Research Service of Veterans Administration (1102-01), Washington, D.C.; Grants HL 13517, HL 19451, and HL 18805 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; and Grant-In-Aid 592-01 from the American Heart Association-Greater Los Angeles.
- 1
Dr. Brown is an Established Investigator of the American Heart Association.
Copyright © 1983 Published by Elsevier Inc.